glipizide has been researched along with Diabetes Mellitus in 76 studies
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In 2009, the Veterans Health Administration (VHA) released a national bulletin regarding the risk of hypoglycemia associated with the use of glyburide in elderly patients with renal dysfunction." | 7.77 | Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide. ( Cantrell, M; Egge, JA; Shaw, RF; Skoff, RA; Waterbury, NV, 2011) |
| "To study some aspects of locally and extraocularly administered methylprednisolone on diffuse diabetic macular edema." | 7.72 | Retrobulbar injection of methylprednisolone in diffuse diabetic macular edema. ( Knudsen, LL, 2004) |
| "Serum fructosamine and blood GHb concentrations are clinically useful tools for monitoring control of glycemia in cats with diabetes mellitus." | 7.70 | Comparison of serum fructosamine and blood glycosylated hemoglobin concentrations for assessment of glycemic control in cats with diabetes mellitus. ( Elliott, DA; Feldman, EC; Neal, LA; Nelson, RW; Reusch, CE, 1999) |
| "Plasma lipid concentration and lipoprotein composition were studied before and after several months of glipizide treatment in 23 patients with non-insulin-dependent diabetes mellitus." | 7.66 | Lipid metabolism in non-insulin-dependent diabetes mellitus: effect of glipizide therapy. ( Doberne, L; Greenfield, MS; Reaven, GM; Rosenthal, M; Vreman, HJ, 1982) |
| "Studies in patients with insulin independent diabetes indicate that treatment with the second generation sulfonylurea glipizide results in partial amelioration of their insulin resistance and that this effect is significant in glipizide's antidiabetic action." | 7.66 | Insulin resistance in patients with insulin independent diabetes mellitus: partial amelioration by the sulfonylurea glipizide. ( Feinglos, MN; Lebovitz, H, 1979) |
| "This study was designed to compare the efficacy of acute premeal administration of glipizide versus nateglinide in controlling postprandial hyperglycemia in subjects with non-insulin-requiring type 2 diabetes." | 5.10 | Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. ( Burge, MR; Carroll, MF; Izard, A; Riboni, K; Schade, DS, 2002) |
| "The addition of sibutramine to oral hypoglycemic therapy resulted in significant weight loss and improvement in metabolic parameters in this patient group." | 5.09 | Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. ( Ertorer, EM; Gokcel, A; Guvener, N; Karakose, H; Tanaci, N; Tutuncu, NB, 2001) |
| "In 13 patients with maturity-onset diabetes mellitus which did not respond to diet therapy alone, serum concentration of glipizide, blood glucose (B-G) concentration, serum immunoreactive insulin (S-IRI) and plasma glycerol (P-G) were monitored hourly over 12 hours after placebo, an initial dose of glipizide (5 mg p." | 5.05 | The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime. ( Christenson, I; Jansson, B; Ostman, J; Weiner, L, 1981) |
| " All of them had maturity-onset diabetes mellitus and were on sulfonylurea drugs (tolbutamide or glipizide)." | 5.05 | A study of the possible interaction of indoprofen with hypoglycemic sulfonylureas in diabetic patients. ( Bommartini, F; Emanueli, A; Freddo, J; Pedrazzi, F, 1981) |
| "In 2009, the Veterans Health Administration (VHA) released a national bulletin regarding the risk of hypoglycemia associated with the use of glyburide in elderly patients with renal dysfunction." | 3.77 | Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide. ( Cantrell, M; Egge, JA; Shaw, RF; Skoff, RA; Waterbury, NV, 2011) |
| "A simple elementary osmotic pump (EOP) system that could deliver metformin hydrochloride (MT) and glipizide (GZ) simultaneously for extended periods of time was developed in order to reduce the problems associated with multidrug therapy of type 2 non-insulin-dependent diabetes mellitus." | 3.73 | Design and evaluation of compound metformin/glipizide elementary osmotic pump tablets. ( Guo, H; Li, W; Liu, H; Nie, S; Ouyang, D; Pan, W, 2005) |
| "To study some aspects of locally and extraocularly administered methylprednisolone on diffuse diabetic macular edema." | 3.72 | Retrobulbar injection of methylprednisolone in diffuse diabetic macular edema. ( Knudsen, LL, 2004) |
| "Glipizide is an oral antidiabetic drug that has been used in the treatment of post-transplant diabetes mellitus (PTDM)." | 3.70 | Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ( Asberg, A; Berg, KJ; Bergan, S; Hartmann, A; Sagedal, S, 1998) |
| "Serum fructosamine and blood GHb concentrations are clinically useful tools for monitoring control of glycemia in cats with diabetes mellitus." | 3.70 | Comparison of serum fructosamine and blood glycosylated hemoglobin concentrations for assessment of glycemic control in cats with diabetes mellitus. ( Elliott, DA; Feldman, EC; Neal, LA; Nelson, RW; Reusch, CE, 1999) |
| "The effect of glipizide treatment on diabetic control and on in vivo insulin secretion and action was studied in 20 patients with non-insulin-dependent diabetes mellitus (NIDDM)." | 3.66 | Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus. ( Doberne, L; Greenfield, MS; Reaven, GM; Rosenthal, M; Schulz, B; Widstrom, A, 1982) |
| "Plasma lipid concentration and lipoprotein composition were studied before and after several months of glipizide treatment in 23 patients with non-insulin-dependent diabetes mellitus." | 3.66 | Lipid metabolism in non-insulin-dependent diabetes mellitus: effect of glipizide therapy. ( Doberne, L; Greenfield, MS; Reaven, GM; Rosenthal, M; Vreman, HJ, 1982) |
| "Studies in patients with insulin independent diabetes indicate that treatment with the second generation sulfonylurea glipizide results in partial amelioration of their insulin resistance and that this effect is significant in glipizide's antidiabetic action." | 3.66 | Insulin resistance in patients with insulin independent diabetes mellitus: partial amelioration by the sulfonylurea glipizide. ( Feinglos, MN; Lebovitz, H, 1979) |
| " Mean initial dosage was 7." | 2.64 | Glipizide in the treatment of maturity-onset diabetes: a multi-centre, out-patient study. ( Fowler, LK, 1978) |
| "The clinically effective duration of blood glucose lowering action of a new hypoglycaemic sulphonylurea, glipizide, given in single before breakfast dosage (up to 20 mg) has been studied in 20 apparently insulin-independent diabetics." | 2.64 | [Duration of effective hypoglycaemic action of glipizide given once daily (author's transl)]. ( Azzopardi, J; Campbell, IW; Clarke, BF; Duncan, LJ, 1975) |
| "Glipizide is a second generation of sulphonylurea compound, effective in lowering of blood glucose, well-tolerated as well as safe during long-term treatment." | 2.39 | [Glipizide--a short-acting sulphonylurea derivative]. ( Ogonowski, J, 1996) |
| "Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide." | 2.36 | Glipizide: a review of its pharmacological properties and therapeutic use. ( Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1979) |
| "Hypoglycemia was defined as hospital admission or an emergency department visit for hypoglycemia or as an outpatient blood glucose <60 mg/dL." | 1.48 | Risk of Hypoglycemia Following Hospital Discharge in Patients With Diabetes and Acute Kidney Injury. ( Abdel-Kader, K; Greevy, RA; Griffin, MR; Horner, J; Hung, AM; Ikizler, TA; Matheny, ME; Parr, SK; Perkins, AM; Roumie, CL; Siew, ED; Speroff, T; Wilson, OD, 2018) |
| "Treatment with metformin and glipizide during in vitro albumin glycation significantly reduced the formation of glycation adducts and inhibited structural modifications." | 1.43 | Antiglycation and cell protective actions of metformin and glipizide in erythrocytes and monocytes. ( Adeshara, K; Tupe, R, 2016) |
| " The mean elimination half-life was 4." | 1.26 | Glipizide pharmacokinetics and response in diabetics. ( Huupponen, R; Iisalo, E; Seppälä, P, 1982) |
| " Food did not affect the bioavailability of any of the four drugs, but delayed Gz absorption." | 1.26 | Kinetics-effect relations of glipizide and other sulfonylureas. ( Melander, A; Sartor, G; Scherstén, B; Wåhlin-Boll, E, 1980) |
| " In accordance with the augmented physiologic insulin release in the morning, a single morning dose of sulfonylureas may be the preferable dosage regimen in the treatment of elderly insulin-independent diabetics of moderate degree." | 1.26 | Diurnal pattern of plasma insulin and blood glucose during glibenclamide and glipizide therapy in elderly diabetics. ( Groop, L; Harno, K, 1980) |
| " Food intake did not influence the peak concentration, the elimination half-life or the bioavailability of the drug." | 1.26 | Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects. ( Melander, A; Sartor, G; Scherstén, B; Wåhlin-Boll, E, 1980) |
| "Ten Type 2 diabetics were examined during long-term treatment, at two dosage levels, with chlorpropamide once daily and glipizide t." | 1.26 | Impaired effect of sulfonylurea following increased dosage. ( Melander, A; Sartor, G; Scherstén, B; Wåhlin-Boll, E, 1982) |
| "Glipizide did not produce glucose variations in either test but did result in a significant decrease, in the first test only, in mean plasma baseline levels of lactate, which were higher than normal in these patients." | 1.26 | Plasma levels of glucose and lactate after intravenous glipizide administration in some insulin-dependent diabetics. Therapeutic effects of an associated glipizide-insulin treatment. ( Boni, C; Buzzigoli, G; Giampietro, O; Navalesi, R, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 50 (65.79) | 18.7374 |
| 1990's | 8 (10.53) | 18.2507 |
| 2000's | 12 (15.79) | 29.6817 |
| 2010's | 6 (7.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hung, AM | 1 |
| Siew, ED | 1 |
| Wilson, OD | 1 |
| Perkins, AM | 1 |
| Greevy, RA | 1 |
| Horner, J | 1 |
| Abdel-Kader, K | 1 |
| Parr, SK | 1 |
| Roumie, CL | 1 |
| Griffin, MR | 1 |
| Ikizler, TA | 1 |
| Speroff, T | 1 |
| Matheny, ME | 1 |
| Cordiner, RLM | 1 |
| Pearson, ER | 1 |
| Tan, A | 1 |
| Holmes, HM | 1 |
| Kuo, YF | 1 |
| Raji, MA | 1 |
| Goodwin, JS | 1 |
| Adeshara, K | 1 |
| Tupe, R | 1 |
| Fritsche, R | 1 |
| Simova-Curd, S | 1 |
| Clauss, M | 1 |
| Hatt, JM | 1 |
| Andersson, C | 1 |
| Gislason, GH | 1 |
| Jørgensen, CH | 1 |
| Hansen, PR | 1 |
| Vaag, A | 1 |
| Sørensen, R | 1 |
| Mérie, C | 1 |
| Olesen, JB | 1 |
| Weeke, P | 1 |
| Schmiegelow, M | 1 |
| Norgaard, ML | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 1 |
| Skoff, RA | 1 |
| Waterbury, NV | 1 |
| Shaw, RF | 1 |
| Egge, JA | 1 |
| Cantrell, M | 1 |
| Carroll, MF | 1 |
| Izard, A | 1 |
| Riboni, K | 1 |
| Burge, MR | 1 |
| Schade, DS | 1 |
| Bleskestad, IH | 1 |
| Birkeland, KI | 1 |
| Ilario, MJ | 1 |
| Turyan, HV | 1 |
| Axiotis, CA | 1 |
| Aronson, D | 1 |
| Mittleman, MA | 1 |
| Burger, AJ | 1 |
| Knudsen, LL | 1 |
| Ouyang, D | 1 |
| Nie, S | 1 |
| Li, W | 1 |
| Guo, H | 1 |
| Liu, H | 1 |
| Pan, W | 1 |
| Mutalik, S | 1 |
| Udupa, N | 1 |
| Kumar, S | 1 |
| Agarwal, S | 1 |
| Subramanian, G | 1 |
| Ranjith, AK | 1 |
| Almér, LO | 2 |
| Scheen, AJ | 1 |
| de la Torre, D | 1 |
| Luyckx, AS | 2 |
| Lefèbvre, PJ | 2 |
| Huupponen, R | 1 |
| Seppälä, P | 1 |
| Iisalo, E | 1 |
| Greenfield, MS | 2 |
| Doberne, L | 2 |
| Rosenthal, M | 2 |
| Schulz, B | 1 |
| Widstrom, A | 1 |
| Reaven, GM | 2 |
| Paisey, RB | 1 |
| Harkness, J | 1 |
| Hartog, M | 1 |
| Chadwick, T | 1 |
| Sartor, G | 4 |
| Melander, A | 5 |
| Scherstén, B | 4 |
| Wåhlin-Boll, E | 4 |
| Groop, L | 3 |
| Harno, K | 1 |
| Fineberg, SE | 1 |
| Schneider, SH | 1 |
| Feinglos, MN | 5 |
| Lebovitz, HE | 3 |
| Tornvall, G | 1 |
| Allgén, LG | 1 |
| Ostman, J | 1 |
| Christenson, I | 1 |
| Jansson, B | 1 |
| Weiner, L | 1 |
| Pedrazzi, F | 1 |
| Bommartini, F | 1 |
| Freddo, J | 1 |
| Emanueli, A | 1 |
| Johansson, E | 1 |
| Tötterman, KJ | 1 |
| Vreman, HJ | 1 |
| Remy, C | 1 |
| Schoos, R | 1 |
| Luyckx, A | 1 |
| Lefèbvre, P | 1 |
| Kuhn, CM | 1 |
| Surwit, RS | 1 |
| Miller, JL | 1 |
| Salman, K | 1 |
| Shulman, LH | 1 |
| Rose, LI | 1 |
| Chidester, PD | 1 |
| Connito, DJ | 1 |
| Ogonowski, J | 1 |
| Riddle, MC | 1 |
| McDaniel, PA | 1 |
| Tive, LA | 1 |
| Cleveland, JC | 1 |
| Meldrum, DR | 1 |
| Cain, BS | 1 |
| Banerjee, A | 1 |
| Harken, AH | 1 |
| Sagedal, S | 1 |
| Asberg, A | 1 |
| Hartmann, A | 1 |
| Bergan, S | 1 |
| Berg, KJ | 1 |
| Elliott, DA | 1 |
| Nelson, RW | 1 |
| Reusch, CE | 1 |
| Feldman, EC | 1 |
| Neal, LA | 1 |
| Sharma, A | 1 |
| Kharb, S | 1 |
| Chugh, SN | 1 |
| Kakkar, R | 1 |
| Singh, GP | 1 |
| Gokcel, A | 1 |
| Karakose, H | 1 |
| Ertorer, EM | 1 |
| Tanaci, N | 1 |
| Tutuncu, NB | 1 |
| Guvener, N | 1 |
| Martin, G | 1 |
| Rand, J | 1 |
| Manohar, V | 1 |
| Talpur, NA | 1 |
| Echard, BW | 1 |
| Lieberman, S | 1 |
| Preuss, HG | 1 |
| Greenwood, RH | 1 |
| Mahler, RF | 1 |
| Hales, CN | 1 |
| Blohmé, G | 1 |
| Waldenström, J | 1 |
| Guirgis, FK | 1 |
| Ghanem, MH | 1 |
| Abdel-Hay, MM | 1 |
| Codaccioni, JL | 1 |
| Fontaine, G | 1 |
| King, JB | 1 |
| Kalk, WJ | 1 |
| Vinik, AI | 1 |
| Jackson, WP | 1 |
| Bracher, M | 1 |
| Jacobs, P | 1 |
| Lecomte, MJ | 1 |
| Fowler, LK | 1 |
| Klaassen, CH | 1 |
| Brogden, RN | 1 |
| Heel, RC | 1 |
| Pakes, GE | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Giampietro, O | 1 |
| Navalesi, R | 1 |
| Buzzigoli, G | 1 |
| Boni, C | 1 |
| Jhran, W | 1 |
| Aman, M | 1 |
| Jawad, F | 1 |
| Sultana, S | 1 |
| Nanji, R | 1 |
| Lebovitz, H | 1 |
| Norris, E | 1 |
| Dowey, KE | 1 |
| Grant, AP | 1 |
| Hayes, JR | 1 |
| Bandisode, MS | 1 |
| Boshell, BR | 1 |
| Azzopardi, J | 1 |
| Campbell, IW | 1 |
| Clarke, BF | 1 |
| Duncan, LJ | 1 |
| Brunová, E | 1 |
| Bucholtz, HK | 1 |
| Lebovitz, FL | 1 |
| Nowotna-Walcowa, R | 1 |
| Szajewski, JM | 1 |
| Walc, J | 1 |
| Di Maria, L | 1 |
| Pini, LA | 1 |
| Prampolini, ML | 1 |
| Deuil, R | 1 |
| Cochet, B | 1 |
| Balant, L | 1 |
| Rilliet, B | 1 |
| Zahnd, G | 1 |
| El Saadani, AM | 1 |
| Gaber, A | 1 |
| Patsch, W | 1 |
| Sailer, S | 1 |
| Braunsteiner, H | 1 |
| Salo, S | 1 |
| Lin, JD | 1 |
| Huang, MJ | 1 |
| Huang, BY | 1 |
| Huang, HS | 1 |
| Ferlito, S | 1 |
| Lunetta, M | 1 |
| Mangiagli, P | 1 |
| Tranchida, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrobulbar Methylprednisolone as Adjunctive Treatment in Optic Neuritis. Randomized Controlled Trial.[NCT04942002] | Phase 2/Phase 3 | 50 participants (Anticipated) | Interventional | 2021-06-15 | Recruiting | ||
| QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia and Glycaemic Variability Determined by Simultaneous Ambulatory Monitoring[NCT02298803] | 30 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
MAGE, a commonly used index of glucose variability, was calculated using data obtained during continuous glucose monitoring. Analysis of correlation between MAGE and delta QTc was undertaken. Please note delta QTc represents the difference between average QTc length during hypoglycemia and average QTc length during normoglycemia. (NCT02298803)
Timeframe: Nocturnal time period (2300-0700) during the 48 hours of Holter monitoring
| Intervention | Correlation coefficient (Number) |
|---|---|
| Hypoglycemia Group | 0.09 |
The day time period for the study spanned from 7 am in the morning until 11 pm in the evening on two consecutive days. The change in the corrected QT interval during day time hypoglycemia was determined by calculating the difference between the average QTc interval length during periods of hypoglycemia (blood glucose level <3.5 mmol/L) and the average QTc interval length during periods of normoglycemia (blood glucose level >3.5 mmol/L) for the day time period. The average QTc interval was calculated using an individually optimised correction formula. If the result of average QTc (hypoglycemia) - average QTc (normoglycemia) was positive, the participant experienced QTc prolongation during hypoglycemia. If the result of average QTc (hypoglycemia) - average QTc (normoglycemia) was negative, the participant experienced QTc shortening during hypoglycemia. (NCT02298803)
Timeframe: Day time period (0700-2300) during the 48 hours of Holter monitoring
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Experienced QTc prolongation during hypoglycemia | Experienced QTc shortening during hypoglycemia | |
| Hypoglycemia Group | 2 | 1 |
deltaQTc is the difference in QTc observed during periods of hypoglycemia and periods of normoglycemia (for those participants who experienced nocturnal hypoglycemia) (NCT02298803)
Timeframe: Nocturnal time period (2300-0700) during the 48 hours of Holter monitoring
| Intervention | milliseconds (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Participant 1 | Participant 4 | Participant 5 | Participant 10 | Participant 15 | Participant 16 | Participant 19 | Participant 24 | |
| Hypoglycemia Group | 10 | 4 | -2 | -6 | -4 | -1 | -8 | 15 |
The MAGE results (in mmol/L) for the eight participants who experienced nocturnal hypoglycemia are included in the table below. (NCT02298803)
Timeframe: 48 hours of continuous glucose monitoring
| Intervention | mmol/L (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Participant 1 | Participant 4 | Participant 5 | Participant 10 | Participant 15 | Participant 16 | Participant 19 | Participant 24 | |
| Hypoglycemia Group | 3.9 | 4.7 | 3.0 | 3.9 | 1.8 | 3.6 | 5.7 | 4.3 |
5 reviews available for glipizide and Diabetes Mellitus
| Article | Year |
|---|---|
Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Rela | 2019 |
[Glipizide--a short-acting sulphonylurea derivative].
Topics: Aged; Diabetes Mellitus; Drug Therapy, Combination; Glipizide; Humans; Hypoglycemic Agents; Insulin; | 1996 |
Current understanding of feline diabetes: part 2, treatment.
Topics: Animals; Blood Glucose; Body Weight; Cat Diseases; Cats; Diabetes Complications; Diabetes Mellitus; | 2000 |
Glipizide: a review of its pharmacological properties and therapeutic use.
Topics: Animals; Diabetes Mellitus; Fatty Acids; Glipizide; Glucagon; Humans; Hypoglycemic Agents; Kinetics; | 1979 |
[Glipizide a new oral antidiabetic agent (comprehensive review)].
Topics: Animals; Blood Glucose; Chemical Phenomena; Chemistry; Diabetes Mellitus; Dogs; Drug Evaluation; Gli | 1976 |
21 trials available for glipizide and Diabetes Mellitus
| Article | Year |
|---|---|
Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Topics: C-Peptide; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glipizide; Huma | 2002 |
Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure.
Topics: Aged; Analysis of Variance; Anti-Arrhythmia Agents; Chi-Square Distribution; Diabetes Complications; | 2003 |
Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and glucose concentrations.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Fasting; Female; Glipizide; Glucos | 1980 |
The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Dose-Response Relationship, Drug; | 1981 |
A study of the possible interaction of indoprofen with hypoglycemic sulfonylureas in diabetic patients.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Double-Bli | 1981 |
Propranolol does not inhibit sulphonylurea-stimulated insulin secretion in patients with non-insulin dependent diabetes mellitus.
Topics: Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus; Double-Blind Method; Fe | 1982 |
Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Me | 1997 |
Evaluation of oxidative stress before and after control of glycemia and after vitamin E supplementation in diabetic patients.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Femal | 2000 |
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus; Double-Blind Meth | 2001 |
Glibenclamide and glipizide in maturity onset diabetes. A double-blind cross-over study.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Double-Blind Method; Female; Glipi | 1979 |
An evaluation of the effects of some sulphonylureas on platelet function.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Female; Gliclazide; Glipizide; Humans; L | 1977 |
Plasma glucagon and clinical control of maturity-onset type diabetes. Effects of diet, placebo and glipizide.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Fatty Acids, Nonesterified; | 1977 |
Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patients.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Female; Fo | 1978 |
Glipizide in the treatment of maturity-onset diabetes: a multi-centre, out-patient study.
Topics: Adult; Aged; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Female; Glipiz | 1978 |
Glipizide ('Glibenese') in maturity-onset diabetes mellitus.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Female; Glipizide; Humans; Male; M | 1979 |
[Clinical experience with Glipizide in a diabetes outpatient department].
Topics: Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Female; Glipizide; Humans; Male; Sulfo | 1977 |
Clinical trial with glipizide in uncomplicated maturity onset diabetes mellitus.
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Female; Glipizide; Humans | 1977 |
Clinical evaluation of a new sulfonylurea in maturity onset diabetes - glipizide (K-4024).
Topics: Adult; Aged; Chlorpropamide; Clinical Trials as Topic; Diabetes Mellitus; Dose-Response Relationship | 1976 |
[Duration of effective hypoglycaemic action of glipizide given once daily (author's transl)].
Topics: Administration, Oral; Aged; Biological Availability; Blood Glucose; Circadian Rhythm; Clinical Trial | 1975 |
[Glipizide: a 2d generation sulfonamide and new antidiabetic].
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Female; Fo | 1975 |
Combination of two sulfonylureas. Does it make sense.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, | 1988 |
50 other studies available for glipizide and Diabetes Mellitus
| Article | Year |
|---|---|
Risk of Hypoglycemia Following Hospital Discharge in Patients With Diabetes and Acute Kidney Injury.
Topics: Acute Kidney Injury; Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetic Nephropathies; Female; | 2018 |
Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Cohort Studies; Diabetes Mellitus; Drug Interactions | 2015 |
Antiglycation and cell protective actions of metformin and glipizide in erythrocytes and monocytes.
Topics: Antioxidants; Cytoprotection; Diabetes Mellitus; Erythrocytes; Glipizide; Glycated Serum Albumin; Gl | 2016 |
Hyperthyroidism in connection with suspected diabetes mellitus in a chinchilla (Chinchilla laniger).
Topics: Animals; Antithyroid Agents; Chinchilla; Diabetes Complications; Diabetes Mellitus; Diagnosis, Diffe | 2008 |
Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Female; Glipizide; Glyburide; Heart Failure; Humans; Hyp | 2011 |
Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide.
Topics: Aged; Blood Glucose; Creatinine; Diabetes Mellitus; Female; Glipizide; Glyburide; Glycated Hemoglobi | 2011 |
[Differences between oral antidiabetics].
Topics: Administration, Oral; Carbamates; Cyclohexanes; Diabetes Mellitus; Glipizide; Humans; Hypoglycemic A | 2003 |
Glipizide treatment with short-term alcohol abuse resulting in subfulminant hepatic failure.
Topics: Alcoholism; Diabetes Complications; Diabetes Mellitus; Fatal Outcome; Female; Glipizide; Humans; Hyp | 2003 |
Retrobulbar injection of methylprednisolone in diffuse diabetic macular edema.
Topics: Administration, Oral; Aged; Aged, 80 and over; Diabetes Mellitus; Diabetic Retinopathy; Glipizide; G | 2004 |
Design and evaluation of compound metformin/glipizide elementary osmotic pump tablets.
Topics: Delayed-Action Preparations; Diabetes Mellitus; Drug Design; Glipizide; Humans; Hypoglycemic Agents; | 2005 |
Glipizide matrix transdermal systems for diabetes mellitus: preparation, in vitro and preclinical studies.
Topics: Acrylic Resins; Administration, Cutaneous; Animals; Cellulose; Diabetes Mellitus; Drug Delivery Syst | 2006 |
Vascular fibrinolytic activity in long term treatment with second generation sulfonylurea compounds.
Topics: alpha-Macroglobulins; Blood Vessels; Chlorpropamide; Diabetes Mellitus; Endothelium; Fibrinolysis; G | 1980 |
[Metabolic and hormonal response to a standardized breakfast in type 2 diabetes. Effect of glipizide].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Female; Food; Glipizide; Humans; Insulin; Male; Middl | 1983 |
Glyburide and glipizide.
Topics: Diabetes Mellitus; Glipizide; Glyburide; Humans; Sulfonylurea Compounds | 1984 |
Glipizide pharmacokinetics and response in diabetics.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Female; Glipizide; Humans; Insulin; Kinetics; Male; M | 1982 |
Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Female; Glipizide; Humans; Insulin; Insulin Resistance; Insu | 1982 |
The effect of improvement in diabetic control on plasma and whole blood viscosity.
Topics: Adolescent; Adult; Blood; Blood Glucose; Diabetes Mellitus; Female; Glipizide; Glyburide; Hemoglobin | 1980 |
Kinetics-effect relations of glipizide and other sulfonylureas.
Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus; Dose-Response Relationship, Drug; Fasting; Feeding | 1980 |
Diurnal pattern of plasma insulin and blood glucose during glibenclamide and glipizide therapy in elderly diabetics.
Topics: Aged; Blood Glucose; Circadian Rhythm; Diabetes Mellitus; Female; Glipizide; Glyburide; Humans; Insu | 1980 |
Sulfonylurea treatment of insulin-independent diabetes mellitus.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diet, Diabetic; Glipizide; Humans; Hypoglycemic Agent | 1980 |
Acute effects of acetylsalicylic acid on blood glucose and insulin in non-insulin dependent diabetes.
Topics: Aspirin; Blood Glucose; Diabetes Mellitus; Female; Glipizide; Humans; Insulin; Male | 1980 |
Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Food; Glipizide; Humans; Insulin; Intestinal Absorption; Ki | 1980 |
Impaired effect of sulfonylurea following increased dosage.
Topics: Aged; Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus; Dose-Response Relationship, Dru | 1982 |
Influence of sulfonylureas on the secretion, disposal and effect of insulin.
Topics: Aged; Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus; Female; Glipizide; Half-Life; Hum | 1982 |
Lipid metabolism in non-insulin-dependent diabetes mellitus: effect of glipizide therapy.
Topics: Aged; Cholesterol; Coronary Disease; Diabetes Mellitus; Female; Glipizide; Humans; Lipid Metabolism; | 1982 |
[Determination of hemoglobin A1c for the evaluation of metabolic equilibrium in patients with non-insulin-dependent diabetes treated with glipizide].
Topics: Blood Glucose; Diabetes Mellitus; Glipizide; Glycosides; Hemoglobin A; Humans; Sulfonylurea Compound | 1980 |
Glipizide stimulates sympathetic outflow in diabetes-prone mice.
Topics: Animals; Diabetes Mellitus; Disease Susceptibility; Glipizide; Liver; Methyltyrosines; Mice; Mice, I | 1995 |
Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes.
Topics: Adult; Aged; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glipizide; Gly | 1993 |
Interaction between glipizide and cyclosporine: report of two cases.
Topics: Adult; Creatinine; Cyclosporine; Diabetes Mellitus; Drug Interactions; Glipizide; Glomerulonephritis | 1993 |
Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.
Topics: Administration, Oral; Aged; Diabetes Mellitus; Female; Glipizide; Glyburide; Heart Atria; Humans; Hy | 1997 |
Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients.
Topics: Adult; Aged; Cyclosporine; Diabetes Mellitus; Drug Interactions; Female; Glipizide; Humans; Hypoglyc | 1998 |
Comparison of serum fructosamine and blood glycosylated hemoglobin concentrations for assessment of glycemic control in cats with diabetes mellitus.
Topics: Animals; Blood Glucose; Cat Diseases; Cats; Cohort Studies; Diabetes Mellitus; Fructosamine; Glipizi | 1999 |
Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice.
Topics: Agaricales; Animals; Blood Glucose; Diabetes Mellitus; Glipizide; Glucans; Hypoglycemic Agents; Insu | 2002 |
Diazoxide, glipizide, and hypoglycaemia.
Topics: Blood Glucose; Diabetes Mellitus; Diazoxide; Drug Antagonism; Glipizide; Humans; Hypoglycemia; Insul | 1977 |
Comparative study of the hypoglycaemic and antilipolytic effects of four antidiabetic agents administered i.v.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glipizide; Glyburide; H | 1976 |
[Diabetes: new drugs?].
Topics: Biguanides; Diabetes Mellitus; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Sulfonylu | 1976 |
Plasma levels of glucose and lactate after intravenous glipizide administration in some insulin-dependent diabetics. Therapeutic effects of an associated glipizide-insulin treatment.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Drug Therapy, Combination; Female; Glipizide; Humans; Injec | 1979 |
Insulin resistance in patients with insulin independent diabetes mellitus: partial amelioration by the sulfonylurea glipizide.
Topics: Blood Glucose; Diabetes Mellitus; Diet, Diabetic; Glipizide; Glucose; Glucose Tolerance Test; Humans | 1979 |
Glipizide: a new second generation sulfonylurea.
Topics: Blood Glucose; Diabetes Mellitus; Diet, Diabetic; Glipizide; Humans; Insulin; Sulfonylurea Compounds | 1979 |
Glipizide evaluation after a one year trial in maturity onset diabetics.
Topics: Aged; Diabetes Mellitus; Drug Evaluation; Glipizide; Humans; Middle Aged; Obesity; Sulfonylurea Comp | 1979 |
Sulphonylureas increase the number of insulin receptors.
Topics: Animals; Diabetes Mellitus; Glipizide; Insulin; Kinetics; Male; Mice; Receptor, Insulin; Sulfonylure | 1978 |
Potentiation of insulin action: a probable mechanism for the anti-diabetic action of sulfonylurea drugs.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Drug Synergism; Female; Glipizide; Humans; Insulin; M | 1977 |
[Evaluation of glipizide].
Topics: Diabetes Mellitus; Drug Evaluation; Glipizide; Humans; Intestinal Absorption; Sulfonylurea Compounds | 1976 |
[Glipizide-phenformin combination in the treatment of diabetes mellitus].
Topics: Aged; Diabetes Mellitus; Drug Combinations; Drug Evaluation; Female; Glipizide; Humans; Male; Middle | 1976 |
[A clinical study of a new sulfonylures hypoglycemic agent: glipizide (glibenese)(author's transl)].
Topics: Acetone; Aged; Blood Glucose; Chemical Phenomena; Chemistry; Delayed-Action Preparations; Diabetes M | 1975 |
Glipizide - another oral hypoglycaemic drug.
Topics: Diabetes Mellitus; Glipizide; Humans; Sulfonylurea Compounds | 1975 |
Glipizide--a new oral antidiabetic.
Topics: Administration, Oral; Adult; Diabetes Mellitus; Female; Glipizide; Humans; Male; Sulfonylurea Compou | 1975 |
[The effect of Glipizide on the blood glucose and insulin in non-ketotic diabetes mellitus (author's transl)].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Glipizide; Humans; Hyperlipidemias; Insulin; Insulin | 1976 |
[Clinical evaluation of the oral hypoglycemic agent glipizide].
Topics: Adult; Aged; Diabetes Mellitus; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Middle Aged; S | 1986 |
[Effects of treatment with glipizide-metformin on the behavior of blood sugar, insulin and lipids after intravenous administration of glucose in diabetic subjects].
Topics: Adult; Blood Glucose; Diabetes Mellitus; Female; Glipizide; Glucose; Humans; Insulin; Lipids; Male; | 1974 |